MYGN240517C21000
- 4.45
- 0.000.00%
Myriad Genetics Newsroom
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men With Localized Prostate Cancer
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.
Myriad Genetics(MYGN.US) Officer Sells US$5.73 Million in Common Stock
$Myriad Genetics(MYGN.US)$ Officer DIAZ PAUL J sold 227.84K shares of common stock on May 13, 14, 15, 2024 at an average price of $25.1434 for a total value of $5.73 million.Source: Announcement What
Myriad Genetics(MYGN.US) Director Sells US$156.86K in Common Stock
$Myriad Genetics(MYGN.US)$ Director Newcomer Lee Nisley sold 6,200 shares of common stock on May 13, 2024 at an average price of $25.3 for a total value of $156.86K.Source: Announcement What is statem
Form 144 | Myriad Genetics(MYGN.US) Officer Proposes to Sell 1.88 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $Myriad Genetics(MYGN.US)$ Officer DIAZ PAUL J intends to sell 75,000 shares of its common stock on May 15, with a total market value of approximately $1.88 million.
Form 144 | Myriad Genetics(MYGN.US) Officer Proposes to Sell 2.39 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $Myriad Genetics(MYGN.US)$ Officer DIAZ PAUL J intends to sell 95,000 shares of its common stock on May 14, with a total market value of approximately $2.39 million.
Form 144 | Myriad Genetics(MYGN.US) Officer Proposes to Sell 1.45 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Myriad Genetics(MYGN.US)$ Officer DIAZ PAUL J intends to sell 57,844 shares of its common stock on May 13, with a total market value of approximately $1.45 million.
Form 144 | Myriad Genetics(MYGN.US) Director Proposes to Sell 156.86K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Myriad Genetics(MYGN.US)$ Director Newcomer Lee Nisley intends to sell 6,200 shares of its common stock on May 13, with a total market value of approximately $156.86K.
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Express News | Piper Sandler Maintains Neutral on Myriad Genetics, Raises Price Target to $28
Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Shares Bounce 26% But Its Business Still Trails The Industry
Myriad Genetics, Inc. (NASDAQ:MYGN) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. Looking back a bit furthe
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
Investors Bid Myriad Genetics (NASDAQ:MYGN) up US$428m Despite Increasing Losses YoY, Taking One-year Return to 36%
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can significantly boost your returns by picking above-average stocks. To wit, the Myriad
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks were slipping late Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing around 0.3%. The iShares Biotechnology ETF (IBB
Myriad Genetics Price Target Raised to $35.00/Share From $25.00 by Leerink Partners
Myriad Genetics Price Target Raised to $35.00/Share From $25.00 by Leerink Partners
Myriad Genetics Raised to Outperform From Market Perform by Leerink Partners
Myriad Genetics Raised to Outperform From Market Perform by Leerink Partners
Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35
Leerink Partners analyst Puneet Souda upgrades Myriad Genetics from Market Perform to Outperform and raises the price target from $25 to $35.
Myriad Genetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 55.73% Leerink Partners $25 → $35 Upgrades Market Perform → Outperform 01/30/2024 37.93% Goldma